Pioglitazone/glimepiride

Drug Profile

Pioglitazone/glimepiride

Alternative Names: AD 4833SU; Duetact; Sonias; Tandemact

Latest Information Update: 16 Mar 2015

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Small molecules; Sulfonylureas; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
  • 10 Jan 2012 The European Commission adopts EMA's CHMP opinion confirming pioglitazone-containing medicines as a valid treatment option for appropriate patients with Type-2 diabetes mellitus
  • 24 Jun 2011 The Committee for Medicinal Products for Human Use of the European Medicines Agency is reviewing the use of pioglitazone-containing medicines in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top